|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.75 HKD | -3.07% |
|
-8.67% | -18.71% |
Innovent Biologics Inc. and Eli Lilly & Co. said the U.S. Food and Drug Administration is currently planning to hold an advisory committee meeting to discuss their biologics license application for sintilimab injection. "FDA Accepts Innovent, Eli Lilly Application for Sintilimab," published at 6:42 a.m. ET, incorrectly reported in the second paragraph that the agency isn't planning such a meeting.
(END) Dow Jones Newswires
05-18-21 0947ET
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 37,735 PTS | -0.65% | -2.89% | - | ||
| 750.8 USD | -0.12% | -3.41% | 676B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -18.71% | 7.43B | |
| -4.17% | 86.99B | |
| +4.34% | 40.68B | |
| -23.95% | 28.61B | |
| +50.44% | 24.1B | |
| -5.09% | 17.37B | |
| -32.11% | 13.72B | |
| -5.10% | 12.49B | |
| -14.91% | 12B | |
| -5.54% | 7.94B |
INNOVENT BIOLOGICS, INC. 
